Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
Targeted Oncology4d
Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC
During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...
Medscape15h
Bladder Cancer Survival Better With Nivolumab Than Placebo in New Analysis
Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
Pharmabiz1d
Merus’ petosemtamab receives US FDA breakthrough therapy designation for 1L PD-L1 positive head and neck squamous cell carcinoma
Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...
emjreviews.com7h
New Strategy Enhances PD-1 Therapy in Treatment-Resistant Cancers
A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
Targeted Oncology1d
FDA Grants Breakthrough Therapy Status to Petosemtamab/Pembrolizumab in HNSCC
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
emjreviews.com13h
Enhancing Immunotherapy by Targeting Specific Receptors in Ovarian Cancer
Discover a study that describes a host-intrinsic mechanism responsible for the failure of PD-L1 blockade in ovarian cancer.
Merus N.V.: Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
This marks the second BTD for petosemtamab in HNSCCUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length mult ...
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2024, as well as ...
7MRUS : Merus Shares Are Up Today: What's Going On?
Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug ...
ascopubs.org25d
Patterns of immune checkpoint inhibitor utilization and PD-L1 testing in advanced gastroesophageal cancers using real-world data.
Epidemiological characteristics of gastric and pancreatic cancers in Latin America: GASPAR (LACOG 0222) study. Comparison of long-term outcomes for neoadjuvant chemoradiation (NA-CRT) followed by ...
BioWorld1d
BA-4415, an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
Researchers from Tianjin University have published data regarding development and preclinical characterization of a new anti-PD-L1/CD40 bispecific antibody (BsAb), BA-4415, designed to activate CD40 ...